Dianthus Therapeutics Finalizes $673.5M Upsized Public Offering, Including Full Underwriter Option Exercise

summarizeSummary

Dianthus Therapeutics finalized its public offering, raising approximately $673.5 million through the sale of common stock and pre-funded warrants, including the full exercise of the underwriters' option, significantly bolstering its financial runway.

check_boxKey Events

• Finalized Public Offering

  Dianthus Therapeutics entered into an underwriting agreement to sell 8,470,989 shares of common stock and 402,468 pre-funded warrants.

• Significant Capital Raise

  The offering is expected to generate approximately $673.5 million in net proceeds, a substantial amount for the company.

• Underwriters' Option Exercised in Full

  The underwriters fully exercised their option to purchase an additional 1,157,407 shares of common stock, contributing to the upsized offering.

• Pricing Details

  Common stock was offered at $81.00 per share, and pre-funded warrants at $80.999, representing a slight discount to the current market price of $86.14.

auto_awesomeAnalysis

This 8-K filing provides the definitive terms of Dianthus Therapeutics' upsized public offering, confirming approximately $673.5 million in net proceeds. This amount is higher than previously reported, reflecting the full exercise of the underwriters' option to purchase additional shares. The offering, priced at $81.00 per share for common stock and $80.999 for pre-funded warrants, represents a modest discount to the current market price of $86.14. This significant capital infusion, following an early "GO decision" in its Phase 3 CAPTIVATE trial and while the stock is trading near its 52-week high, substantially strengthens the company's financial position and provides a long runway for continued development, particularly for its lead asset, claseprubart. While dilutive, the successful and upsized nature of the offering, coupled with strong demand indicated by the full option exercise, suggests investor confidence in the company's prospects.